Georgia SB 220 Watch — The May 12, 2026 Decision Window

Last verified: May 2026

The Three-Bill Cannabis Package on Kemp’s Desk

As of mid-April 2026, three cannabis-policy bills sit on Gov. Brian Kemp’s desk awaiting his ~May 12, 2026 signature decision:

• SB 220 — medical-cannabis program expansion. See SB 220 page.
• SB 33 — synthetic hemp products ban (HHC etc.) by 2027.
• SB 254 — amended on Senate floor 29-27 to ban THC-infused beverages entirely.

The three bills together represent a comprehensive cannabis-policy package: SB 220 expands medical access, while SB 33 and SB 254 tighten the hemp framework.

The SB 220 Provisions in Brief

• Renames "low THC oil" to "medical cannabis" throughout state law.
• Removes the 5% THC potency cap.
• Imposes a 12,000 mg total-THC possession ceiling at any one time, with individual product packages capped at 1,200 mg.
• Authorizes vaporization for patients 21 and older, in private settings, no later than January 1, 2027.
• Adds lupus, severe arthritis, and severe insomnia as qualifying conditions.
• Removes "severe or end-stage" qualifier from cancer, MS, Parkinson’s, Alzheimer’s, and others.
• Tightens physician oversight by requiring certifying physicians to maintain a "principal place of practice" in Georgia.

If signed, Georgia will move from the most restrictive U.S. medical cannabis program to one closer in design to Tennessee’s hemp regime than to Florida’s full-spectrum program. Cannabis flower and conventional edibles would still be banned even after SB 220.

Kemp’s Three Options

• Sign: SB 220 takes effect on the statutory effective date; vaporization triggers no later than January 1, 2027. SB 33 and SB 254 take effect on their respective effective dates.
• Veto: The General Assembly could attempt 2/3 override (38 Senate votes, 120 House votes). Override is historically rare in Georgia; both chambers need to be willing to break with the Governor’s position.
• Allow to become law without signature: Same effect as a sign — the bill becomes law.

Gov. Kemp has signaled openness to SB 220’s milligram-based framework. He has been more cautious on broader recreational reform, but the SB 220 package is a medical-program expansion within the existing constitutional and statutory architecture.

Why This Decision Is Pivotal for Patients

Georgia’s adoption rate is the lowest of any U.S. medical-cannabis program (~0.3% of population). The structural reasons — 5% THC cap, no smokable flower or edibles, the "low THC oil" naming, "severe or end-stage" qualifiers — are all addressed by SB 220. If signed, registry adoption is expected to rise materially over 2026–2027.

• The 5% THC cap removal would allow higher-potency oil products and concentrate-equivalents.
• Vaporization authorization would add the first legal inhalation pathway for Georgia patients (smoking remains banned).
• Lupus + severe arthritis + insomnia additions would bring tens of thousands of additional patients into eligibility.
• Removing "severe or end-stage" qualifier would expand eligibility for documented but moderate cancer, MS, Parkinson’s, and Alzheimer’s patients.

The Hemp Tightening Side

SB 33 and SB 254 would tighten Georgia’s already-restricted hemp framework further:

• SB 33 bans synthetic cannabinoids (HHC, certain forms of THCP, lab-manufactured analogs) by 2027 while preserving naturally-derived Delta-8.
• SB 254 bans THC-infused beverages entirely — eliminating the nascent Georgia hemp-beverage retail market.

What to Watch

• Gov. Kemp’s May 12, 2026 announcement on each bill.
• If SB 220 is signed: GMCC and DPH implementation timeline; updates to physician certification protocols.
• If SB 220 is vetoed: General Assembly override attempt math (current Republican supermajorities in both chambers).
• If SB 33 or SB 254 are signed: GDA enforcement preparation for the hemp-product transition.
• Federal Schedule III rescheduling status (separate timeline; pending administrative finalization).
• Federal Farm Bill amendments (November 12, 2026 implementation date for new total-THC restrictions).